17:56:45 EDT Tue 20 Oct 2026
Enter Symbol
or Name
USA
CA



Ovation Science Inc
Symbol OVAT
Shares Issued 38,411,681
Close 2026-10-16 C$ 0.03
Market Cap C$ 1,152,350
Recent Sedar+ Documents

Ovation Science appoints Chypyha as CFO

2026-10-20 14:31 ET - News Release

Subject: Press Release/News Attached for Distribution on Stockwatch.com PDF Document

File: Attachment NR Apnt Joan Chypyha - CFO.v3.pdf

OVATION SCIENCE INC. ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICER

Vancouver, BC and Las Vegas, NV October 20, 2026 Ovation Science Inc. (CSE: OVAT / OTC: OVATF) ("Ovation" or the "Company") is pleased to announce that it has appointed Joan Chypyha as Chief Financial Officer of the Company, effective immediately.

Ms. Chypyha brings over 30 years of executive and operational management experience across the pharmaceutical and biotechnology sectors. She is the founder, President and Chief Executive Officer of Alto Pharmaceuticals Ltd., where she leads commercial strategy, business operations and financial management. Alto Pharmaceuticals Ltd. holds an interest in Pepper & Pink Inc., a company focused on launching branded and private label personal care products.

Her background includes serving as President of Cipher Pharmaceuticals, General Manager at Barrier Therapeutics Canada and 16 years at Hoffmann-La Roche in senior leadership, business development and strategic operational roles, including as Director of the Dermatology Business Unit. Ms. Chypyha also brings public company governance experience, including as an independent director and audit committee member of Edesa Biotech, Inc. This experience encompasses financial oversight, regulatory compliance, capital allocation and public market strategy. Ms. Chypyha has served as a director of the Company and will continue to serve on the board of directors.

In connection with her appointment, Ms. Chypyha has resigned as a member of the Company's audit committee, effective concurrently with her appointment as Chief Financial Officer. The board of directors has appointed Ronald Stern to the audit committee to fill the resulting vacancy.

ON BEHALF OF THE BOARD OF DIRECTORS

Terry Howlett Chief Executive Officer and director

About Ovation Science Inc.

Ovation Science Inc., together with its wholly-owned subsidiary, Ovation Science USA Inc., is a research and development company that develops topical and transdermal CBD/THC and other cannabinoid products which are out-licensed and also distributed under Ovation's own brands, ARLO CBD Beauty and InVibetrademark MD ("wellness" line), all powered by its patented Invisicaretrademark skin delivery technology. Invisicare enhances the delivery of ingredients to and through the skin and is protected by patents and proprietary formulations. With over 20 years of pharmaceutical drug delivery experience, Ovation's management and science team have created a unique pipeline of proprietary medical / wellness topical and transdermal products along with a line of anti-aging / beauty formulas. Ovation earns revenues from royalties on licensees' sales and the sale of Invisicare, along with revenue from its own product sales. Ovation has offices in Vancouver, Canada and Las Vegas, USA.

Stock symbols: CSE: OVAT / OTC: OVATF Websites: CORPORATE: www.ovationscience.com WELLNESS: www.invibemd.com BEAUTY: www.arlocbdbeauty.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release.

CORPORATE and LICENSING INQUIRIES

Terry Howlett: info@ovationscience.com

© 2026 Canjex Publishing Ltd. All rights reserved.